Donna Grogan

Donna Grogan, M.D., has served as a member of the Board of Directors since August 2022. Dr. Grogan currently serves as Principal of Grogan Consulting LLC where she supports clients across drug development, regulatory strategy, trial design, and data interpretation. Between September 2013 and June 2019, Dr. Grogan served as Chief Medical Officer of Clementia Pharmaceuticals, which was acquired by Ipsen in April 2019. She previously served as Chief Medical Officer for several HealthCare Ventures portfolio companies including Anexon, Apofore, and DecImmune. Between February 2007 and August 2011, Dr. Grogan served as Chief Medical Officer, and Senior Vice President of Clinical Development at FoldRx Pharmaceuticals, which was acquired by Pfizer in October 2010. Earlier in her career, she held roles of increasing responsibility at Sepracor Inc. where she was involved in multiple high-profile product approvals including Lunesta®, Xopenex HFA®, and Brovana™. Dr. Grogan previously served as a board member, including membership on the Compensation Committee and the Scientific Committee, of Momenta Pharmaceuticals until it was acquired by J&J in October 2020. She holds an M.D. from the University of Illinois College of Medicine and a B.A. from the College of the Holy Cross.